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Summary
Background.— The discovery of angiotensin-converting enzyme 2 (ACE2) has greatly modiﬁed
understanding of the renin-angiotensin system (RAS).
Aims.— To investigate the cardiac expression of ACE2 and ACE in spontaneously hypertensive
rats (SHRs) and the effects of enalapril on them.
Methods.— Fifteen SHRs were randomly assigned to two groups: an SHR control group (n = 7),inhibitors;
Enalapril
treated with vehicle; and an enalapril group (n = 8), treated with enalapril (15mg/kg/day). After
4weeks of treatment, the rats were killed and the left ventricular tissue was dissected. Reverse
transcription-polymerase chain reaction and Western blot protein staining were performed to
detect expression of ACE2 and ACE messenger ribonucleic acid (mRNA) and protein. Ten Wistar
Kyoto rats (WKYs) served as the normotensive control group, which were treated with vehicle.
Abbreviations: ACE, angiotensin-converting enzyme; RAS, renin-angiotensin system; ACEI, angiotensin-converting enzyme inhibitor;
RB, angiotensin receptor blocker; EF, elongation factor; mRNA, messenger ribonucleic acid; PBS, phosphate-buffered solution; SHR,
pontaneously hypertensive rat; RT-PCR, reverse transcription-polymerase chain reaction; WKY, Wistar Kyoto.
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Results.— Compared with in normotensive WKYs, cardiac expression of ACE mRNA and protein
in SHRs was increased (1.68± 0.34 vs. 0.33± 0.12, P < 0.05 and 1.21± 0.14 vs. 0.71± 0.11,
P < 0.05, respectively), whereas cardiac expression of ACE2 mRNA and protein was decreased
(0.50± 0.15 vs. 1.16± 0.24, P < 0.05 and 0.71± 0.24 vs. 1.22± 0.14, P < 0.05, respectively).
After treatment with enalapril, the levels of ACE mRNA and protein were decreased (0.44± 0.19
vs. 1.68± 0.34, P < 0.01 and 0.87± 0.13 vs. 1.21± 0.14, P < 0.05, respectively), the level of
ACE2 mRNA was increased (1.77± 0.49 vs. 0.50± 0.15, P < 0.05) but the level of ACE2 protein
remained unchanged.
Conclusions.— In SHRs, the expression of cardiac ACE was remarkably increased, whereas ACE2
was notably decreased. Reduction of ACE and elevation of ACE2 might be one of the mechanisms
underlying the antihypertensive function of enalapril.
© 2013 Elsevier Masson SAS. All rights reserved.
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Résumé
Justiﬁcation.— La découverte de l’enzyme de conversion de l’angiotensine 2 (ACA2) a modiﬁé
de fac¸on substantielle la compréhension du système rénine-angiotensine (RAS).
Objectifs.— Évaluer l’expression cardiaque de l’ACE 2 et de l’ACE chez des rats spontanément
hypertendus (SHRs) ainsi que les effets de l’énalapril sur leur expression.
Méthode.— Quinze rats spontanément hypertendus ont été randomisés en deux groupes: SHR
contrôle (n = 7) non traités et SHR traités par énalapril (n = 8) a une dose de 15mg/kg par jour.
Après quatre semaines de traitement, les reins ont été sacriﬁés et le myocarde ventriculaire
gauche a été analysé. Une PCR et un western blot ont été effectués pour détecter l’expression
de l’ACE2 et du messager de l’ACE (RNAm) ainsi que la protéine correspondante. Dix rats Kyoto
Wistar (WKYs) ont servi de groupe de témoin normotendu, non traité.
Résultats.— Comparativement aux rats normotendus WKYs, l’expression cardiaque de
l’ARM messager de l’ACE et la protéine chez les rats hypertendus (SHRs) étaient
augmentées (1,68± 0,34 versus 0,33± 0,12, p < 0,05 et 1,21± 0,14 versus 0,71± 0,11,
p < 0,05 respectivement). Tandis que l’expression cardiaque de l’ARM messager de l’ACE2 et
la protéine était diminuée (0,50± 0,15 versus 1,16± 0,24, p < 0,05 et 0,71± 0,24 versus
1,22± 0,14, p < 0,05 respectivement). Après traitement par énalapril, les concentrations
d’ARM messager de l’ACE et de la protéine étaient diminués (0,44± 0,19 versus 1,68± 0,34,
p < 0,01 et 0,87± 0,13) versus l’ACE2 était augmentée (1,77± 0,49 versus 0,50± 0,15, p < 0,05)
mais la concentration de protéine ACE2 n’était pas modiﬁée.
Conclusion.— Chez des rats SHRs, l’expression de l’ACE cardiaque est augmentée de fac¸on
signiﬁcative tandis que celle de l’ACE 2 est diminuée de fac¸on signiﬁcative. La réduction de
l’ACE et l’élévation de l’ACE2 serait un des mécanismes sous tendant l’effet antihypertenseur
de l’énalapril.
© 2013 Elsevier Masson SAS. Tous droits réservés.
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The discovery of angiotensin-converting enzyme 2 (ACE2)
[1,2] has changed our understanding of the renin-
angiotensin system (RAS). During the past decade, ACE2
has attracted more and more attention and is gradually
becoming a new focus of research. ACE2 is one of the key
enzymes in RAS that play important roles in the regula-
tion of blood pressure and maintenance of cardiac function;
it has gradually come to be considered as one of the
new targets for the treatment of cardiovascular disease
[3—6].There is increasing evidence that ACE2 is closely related
to hypertension. Blocking agents of RAS, such as ACE
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs),
can elevate the level of ACE2 [7].
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MIt will be more informative and persuasive if ACE2 can
e studied, not only horizontally together with ACE but
lso vertically, at the levels of transcription and transla-
ion. Moreover, different ACEIs might, to a certain extent,
ave various pharmacological effects and thereby different
ffects on ACE2. So it is still necessary to study the dif-
erent effects of different ACEIs on ACE2/ACE, which may
nrich our understanding of the pharmacological effects of
CEIs.
In this study, we used spontaneously hypertensive rats
SHRs) as the animal model and Wistar Kyoto rats (WKYs) as
he control group. Reverse transcription-polymerase chain
eaction (RT-PCR) and Western blot protein staining were
mployed to detect cardiac ACE and ACE2, facilitating study
f the possible role played by ACE2 in hypertension in SHRs.
oreover, to explore in depth the mechanisms of ACEIs,
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Table 1 Primer pairs for ACE, ACE2 and EF1 messenger ribonucleic acid.
Gene Primer sequence Size (bp) Total circlesa
ACE Forward 5′-TTGACGTGAGCAACTTCCAG-3′ 421 30 (13)
Reverse 5′-GGCTGCAGCTCCTGGTATAG-3′
ACE2 Forward 5′-GTGCACAAAGGTCACAATGG-3′ 410 30 (14)
Reverse 5′-TGTTTCATCATGAGGCAGAGG-3′
EF1 Forward 5′-GGAATGGTGACAACATGCTG-3′ 347
Reverse 5′-CGTTGAAGCCTACATTGTCC-3′
ACE: angiotensin-converting enzyme; bp: base pairs; EF: elongation factor.
a The number of ampliﬁcation cycles performed for the speciﬁc target gene. The primer pairs for the EF1 control were added after
the number of cycles indicated in parentheses.
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wnalapril was used to treat SHRs and its effects on cardiac
CE and ACE2 were investigated.
ethods
nimals
ifteen male SHRs (Shanghai laboratory animal centre), aged
6weeks and with an average body weight of 39± 21 g, were
andomized into two groups: an SHR control group (n = 7),
reated with vehicle; and an SHR enalapril group (n = 8),
reated with enalapril (15mg/kg/day). Treatment lasted
or 4weeks. During the treatment period, body weight and
ail blood pressure were measured once per week and the
nalapril dose was adjusted based upon body weight. Ten
KYs served as the normotensive control group and were
lso treated with vehicle. At the end of treatment, the rats
ere killed and the left ventricles were dissected carefully
nd frozen and stored in liquid nitrogen for RT-PCR and West-
rn blot protein staining.
The study was approved by the Animal Care and Use
ommittee of Suzhou University and our study followed the
rinciples in the Declaration of Helsinki.
solation of total ribonucleic acid and reverse
ranscription-polymerase chain reaction
otal RNA was isolated according to the Trizol reagent
anual and reverse transcription was performed using
oloney murine leukaemia virus reverse transcriptase in
mixture containing deoxyribonucleotides, random hex-
mers and ribonuclease inhibitor in reverse transcriptase
uffer. Elongation factor 1 (EF1) was used as the internal
tandard. The PCR assay was performed using the primers
or ACE, ACE2 and EF1 described by Sakima et al. [8]
Table 1). The PCR ampliﬁcation conditions (30 cycles) were
s follows: denaturing, 94 ◦C for 90 seconds; annealing, 56 ◦C
or 45 seconds; elongation, 72 ◦C for 45 seconds. Primers
or EF1 were added to all reactions at the cycle number
ndicated in Table 1. Finally, an elongation was performed
t 72 ◦C for 10minutes. Ampliﬁcation products were sep-
rated on a 1% agarose gel dyed by Loading Dye I. The
ands were visualized and the optical density was quantiﬁed
i
b
w
by the Bio-Rad computerized densitometry system (Bio-Rad
aboratories, Inc., Hercules, CA, USA). The target messen-
er ribonucleic acid (mRNA) concentration was expressed
s the ratio of target gene to the internal standard EF1
ene.
estern blot
he membrane protein was isolated using cell lysis buffer
ontaining a proteinase inhibitor mixture. Protein concen-
ration was determined using the Bradford method. Sample
roteins (10g/lane) and a prestained protein weight
arker were loaded and size fractionated by sodium dodecyl
ulphate polyacrylamide gels. The proteins were then
ransferred from the gel onto nitrocellulose membranes
nd blocked with 1% non-fat skimmed milk in phosphate-
uffered solution (PBS) for 45minutes at room temperature
nder gentle agitation on a shaker. The membranes were
hen incubated overnight at 4 ◦C with the primary anti-
ody (1:200, Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
SA) in PBS containing 0.5% non-fat skimmed milk buffer.
n the following day, the membranes were thoroughly
ashed three times (10minutes each) using PBS contain-
ng 0.1% Tween. Positive bands were developed using the
estern Blotting Analysis System (Tiandz, Beijing, China)
n which horseradish peroxidase-conjugated secondary anti-
ody was diluted at 1/10,000 and incubated for 1 hour at
oom temperature. The membranes were then visualized by
hemiluminescence and photographed using an x-ray. The
rotein bands on the x-ray ﬁlms were quantiﬁed by den-
itometry scanning and corrected for -actin. The target
rotein was expressed as the ratio of target protein to -
ctin.
tatistical analysis
ata were analysed using SPSS 11.0 software. Each value
as expressed as mean± standard error of the mean. Signif-cant differences were obtained when P < 0.05. Differences
etween two groups were analysed using the t test. One-
ay analysis of variance was used to analyse the differences
etween multiple groups.
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Table 2 Blood pressure before and after treatment in different groups.
Group n Blood pressure (mmHg)
Base value 1st week Pa 2nd week Pa 3rd week Pa 4th week Pa
WKY group 10 122 ± 14 124 ± 10 0.664 118 ± 13 0.887 120 ± 15 0.774 116 ± 4 0.901
SHR control group 7 188 ± 24 187 ± 17 0.421 189 ± 18 0.413 185 ± 15 0.401 187 ± 11 0.442
SHR enalapril group 8 195 ± 16 150 ± 11 < 0.001 140 ± 9 < 0.001 140 ± 12 < 0.001 138 ± 11 < 0.001
Blood pressure data are mean± standard error of the mean. SHR: spontaneously hypertensive rat; WKY: Wistar Kyoto rat.
a Compared with blood pressure before treatment within the same group. Data were analyzed with pairwise comparisons.
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ACE2 was markedly lower in SHRs than in WKYs. These dataResults
Effects of enalapril on blood pressure in
spontaneously hypertensive rats
Blood pressure in SHRs was markedly higher than that in
WKYs (P < 0.05). Enalapril signiﬁcantly reduced blood pres-
sure in SHRs (P < 0.05) (Table 2).
Effects of enalapril on cardiac
angiotensin-converting enzyme and
angiotensin-converting enzyme2 messenger
ribonucleic acid in spontaneously
hypertensive rats
The cardiac expression of ACE mRNA was markedly higher
and of ACE2 mRNA was signiﬁcantly lower in SHRs than in
WKYs (1.68± 0.34 vs. 0.33± 0.12, P < 0.05 and 0.50± 0.15
vs. 1.16± 0.24, P < 0.05, respectively). Enalapril markedly
reduced the expression of ACE mRNA (0.44± 0.19 vs.
1.68± 0.34, P < 0.05) and signiﬁcantly increased the expres-
sion of ACE2 mRNA (1.77± 0.49 vs. 0.50± 0.15, P < 0.05)
(Fig. 1).
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Figure 1. Cardiac angiotensin-converting enzyme (ACE) 2 and ACE me
the spontaneously hypertensive rat (SHR) control group (C) and the SHR e
in SHRs (P < 0.05). Enalapril signiﬁcantly reduced the expression of ACE
analyzed with analysis of variance and pairwise comparisons. P-values s
C.  P < 0.05 vs. W.ffects of enalapril on cardiac
ngiotensin-converting enzyme and
ngiotensin-converting enzyme2 proteins in
pontaneously hypertensive rats
he cardiac expression of ACE protein was markedly higher
nd of cardiac ACE2 protein was signiﬁcantly lower in
HRs than in WKYs (1.21± 0.14 vs. 0.71± 0.11, P < 0.05 and
.71± 0.24 vs. 1.22± 0.14, P < 0.05, respectively). Enalapril
arkedly reduced the expression of ACE protein (0.87± 0.13
s. 1.21± 0.14, P < 0.05) but had no statistically signiﬁcant
mpact on the expression of ACE2 protein (0.42± 0.22 vs.
.71± 0.24, P > 0.05) (Fig. 2).
iscussion
n this study, we investigated the cardiac expression of ACE
nd ACE2 mRNA and protein in SHRs; the results showed that
ardiac expression of ACE was signiﬁcantly higher and ofuggest that the imbalance between ACE and ACE2 might
lay a critical role in the pathophysiology of hypertension in
HR.
ssenger ribonucleic acid (mRNA) in the Wistar Kyoto rat group (W),
nalapril group (E). ACE mRNA elevated and ACE2 mRNA decreased
mRNA and elevated the level of ACE2 mRNA (P < 0.05). Data were
howed signiﬁcance among the pairwise comparisons. * P < 0.05 vs.
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Figure 2. Effects of enalapril on angiotensin-converting enzyme (ACE) 2 and ACE proteins. ACE protein elevated and ACE2 protein
decreased in SHRs (P < 0.05). Enalapril signiﬁcantly decreased the expression of ACE protein (P < 0.05), yet had no statistically signiﬁcant
impact on the level of ACE2 protein (P > 0.05). C: spontaneously hypertensive rat control group; W: Wistar Kyoto rat group; E: enalapril group.
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In 2000, ACE2 — a human homologue of ACE — was
iscovered and reported by two groups, independently of
ach other, using differing genomic-based strategies [1,2].
CE2 is a zinc metalloprotease and its gene maps to the X
hromosome. Like ACE [9], ACE2 is a strong candidate for
hypertensive quantitative trait locus. In early research,
CE2 was found to be expressed in heart and kidney [1].
ate studies indicated that it was also expressed in the testes
10], gastrointestinal tract [11] and lungs [12].
Although ACE and ACE2 are homologues, their functions
re notably different. Studies showed that the average blood
ressure in mice with the ACE2 gene knocked out was
0mmHg higher than in controls [13]. Moreover, in SHRs
nd stroke-prone SHRs, ACE2 expression was lower than
hat in normotensive WKYs. On the other hand, WKYs had
igh expression of ACE2 [14]. The decrease in ACE2 can
ead to acceleration of the progression of hypertension in
oldblatt hypertensive rats [3]. All of these ﬁndings suggest
hat ACE2 has antihypertensive effects. From our study, we
nferred that the reduced ACE2 in SHRs can lead to impaired
ntihypertensive effects of ACE2, which is conducive to
ypertension.
The main function of ACE2 is to produce Ang-1—7, which
as peripheral vasodilative and antiproliferative actions
15]. ACE2 cleaves a single amino acid from angiotensin
I to generate Ang-1—7 [16]. ACE2 also cleaves an amino
cid from the C-terminal of angiotensin I to generate Ang-
—9. Ang-1—9 is afterwards cleaved by ACE or another
ipeptidase into Ang-1—7 and other angiotensin peptides.
ng-1—7 reduces artery pressure dose-dependently [17],
mpliﬁes the vasodilator actions of bradykinin [18], accel-
rates the degradation of angiotensin II [5] and attenuates
he formation of reactive oxygen species [4]. Through a
radykinin/nitric oxide-mediated mechanism that stimu-
ates cyclic guanosine monophosphate/protein kinase G
ignalling, Ang-1—7 reduces the release of norepinephrine
15] and increases the release of nitric oxide from platelets
19], thereby dilating the vessels indirectly.In addition to blood pressure-lowering effects, Ang-1—7
an also prevent angiotensin II-mediated cardiac remod-
lling [20]. One study showed that subcutaneous admin-
stration of the ACE2 inhibitor MLN-4760 (30mg/kg/day)
e
s
a
s. P-values showed signiﬁcance among the pairwise comparisons. *
ia mini-osmotic pumps for 28 days increased the level
f angiotensin II by 24%, which exacerbated cardiac
ypertrophy and ﬁbrosis [21]. ACE2 deﬁciency due to
CE2 gene knockout exacerbated hypertension, myocardial
ypertrophy, ﬁbrosis and diastolic dysfunction, which were
nduced by angiotensin II infusion. In summary, ACE2 is an
mportant negative regulator of angiotensin II-induced heart
isease [22].
Our study also explored the effects of enalapril on car-
iac expression of ACE and ACE2 mRNA and protein. The
esults showed that enalapril reduces the expression of ACE
t transcriptional and translational levels, increases ACE2
xpression at transcriptional level alone but has no marked
ffects on ACE2 protein. In other words, upregulation of
ardiac ACE2 mRNA did not lead to upregulation of ACE2
rotein.
This lack of parallel between mRNA, protein and enzy-
atic activity has been reported previously. For example,
errario et al. [7] explored the effects of lisinopril and losar-
an, alone and in combination, on cardiac ACE and ACE2
n normotensive Lewis rats. The results showed that losar-
an signiﬁcantly increased ACE2mRNA and activity. Lisinopril
lso upregulated ACE2 mRNA but had no marked effects on
CE2 activity. When lisinopril and losartan were used in com-
ination, although ACE2 activity increased as in the group
n which losartan was used alone, no evident increase in
CE2 mRNA was found. Additional research is needed to fur-
her deﬁne the mechanisms behind the absence of parallel
etween ACE2 mRNA and protein.
ACE and ACE2 are two products with opposite func-
ions and together they maintain normal blood pressure.
n hypertension, ACE is increased and ACE2 is decreased.
t is reasonable for enalapril, an ACEI, to inhibit the activ-
ty of ACE. Why did enalapril increase ACE2 mRNA? In our
tudy, after treatment with enalapril, the expression of
CE2 mRNA increased even beyond the values in normoten-
ive WKYs. This implied that the increase in ACE2 was
ore than a reﬂection of the down-regulation of ACE. How-
ver, the mechanisms by which ACEIs increase ACE2 are
till unclear. In terms of pathology, the decrease in ACE
nd the increase in ACE2 favour the control of blood pres-
ure. This sort of effect that enalapril has on ACE and ACE2
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[
[
[Enalapril and expression of ACE in hypertensive rats
might play a critical role in the antihypertensive functions
of ACEIs.
Conclusions
Our study showed that in SHRs, the cardiac expression of
ACE mRNA and protein was remarkably increased, whereas
that of ACE2 mRNA and protein was notably decreased.
Enalapril markedly reduced ACE and signiﬁcantly elevated
ACE2. These ﬁndings suggest that the antihypertensive and
cardiac protective functions of ACEIs may be due, in part,
to elevation of ACE2.
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